Company intelligence / Profile preview

Tcoag

Ownership: Private
Development stage: Commercial

Overview

Tcoag develops, manufactures, and markets advanced coagulation testing systems—including reagents, instruments, and consumables—used in clinical laboratories for the diagnosis of thrombosis, hemostasis disorders, and related conditions. Their products are widely used globally with a strong reputation for quality instrumentation such as the Destiny and DT100 analyzer lines[1][2].

Therapeutic areas: CardiovascularHematology
Modalities: DeviceDiagnostic reagentDiagnostic instrument (immunoturbidimetric, mechanical and optical clot detection)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

TriniLIA D-Dimer II

Commercial

Indications: Venous thromboembolism

Partnerships

Distributors worldwide including Medica-Tec in Argentina[4]

Beyond the preview

Go deeper on Tcoag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tcoag.

Explore the full profile